By reading this article, you should be able to:
patients are asymptomatic or have minor symptoms such as palpitations, whereas others may present with a complication such as an ischaemic stroke. About 20% of strokes are attributed to AF. AF is classified according to its duration: paroxysmal AF ends spontaneously (within 48 h) or within 7 days after treatment. Persistent AF is defined as continuing 7 days, whereas longstanding persistent AF is defined as lasting 1 yr. AF reduces left ventricular filling and cardiac output; it can cause thromboembolic events, cognitive impairment, and vascular dementia, despite anticoagulation.
Pathophysiology
There is a genetic predisposition to AF, especially early onset. Alcohol dependence and congenital heart disease are also risk factors. Slow progressive atrial remodelling produces electrical dissociation between muscle bundles and local conduction pathways, resulting in re-entry conduction and arrhythmias. The left atrium dilates with stasis of blood flow and thrombus formation, of which the left atrial appendage (LAA) is the main site. Haïssaguerre and colleagues noted that the four pulmonary vein (PV) ostia were focal sources that triggered AF. 3 
Treatment
It is important to consider the five domains in the management of AF (Fig. 1 ).
Anticoagulation
Oral anticoagulation prevents thromboembolic complications. Warfarin or direct acting oral anticoagulants (DOACs) (direct thrombin inhibitors or activated factor X inhibitors) prevent ischaemic strokes at the risk of increased bleeding. 4 The European Society for Cardiology guidelines from 2010 estimate stroke risk, using the CHA2DS2-VASc [Congestive heart failure; Hypertension; Age 75 yr; Diabetes mellitus; prior stroke (S 2 ), transient ischaemic attack (TIA), or thromboembolism; Vascular disease; Age 65e74 yr; Sex category] score (Table 1) . 5 AF with no clinical risk factors does not require anticoagulation. A CHA2DS2-VASc score of 1 in males and 2 in females will benefit from OAC therapy. Warfarin reduces stroke risk by 66% and mortality by 25% compared to aspirin or no therapy. 6 The novel OACs have a similar efficacy to warfarin, with a lower risk of cerebral haemorrhage. The HAS-BLED score is commonly used to assess the risk of bleeding ( Table 2) . A score of 3 implies a high bleeding risk but is not a contraindication to OACs. Clinicians must balance between reducing stroke and thromboembolism with the risk of a significant bleed (intracranial haemorrhage).
LAA closure devices
In patients with a significant bleeding risk (HAS-BLED Score >3) and a relative contraindication to OACs (such as intracranial haemorrhage, coagulation disorders, gastrointestinal bleeding, renal failure, and non-compliance with medication), a LAA percutaneous closure device should be considered. A LAA closure device is a plug that is guided transvenously into the LAA to obliterate the cavity and prevent thrombus formation. Transoesophageal echocardiography (TOE) is required before the procedure to confirm that the LAA is free from thrombus ( Fig. 2) , and afterwards to assess device position. Incomplete occlusion occurs in up to 50% of cases, leaving the patient at continued risk of thromboembolism.
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Management of AF
Step 1
Control heart rate Β-blockers, digoxin, calcium channel blockers Decrease symptoms and may preserve cardiac function
Has not shown to reduce mortality and morbidity
Step 2
Identify precipitating factors
Treat sepsis and thyrotoxicosis
Step 3
Control associated cardiovascular symptoms
Hypertension, heart failure, ischaemic heart disease, valvular heart disease, diabetes mellitus, chronic kidney disease, obesity
Step 4
Thromboprophylaxis with oral anticoagulation or left atrial appendage closure devices
Step 5
Rhythm control with electrical or chemical cardioversion At present there are four percutaneous LAA occlusion devices available. 8 The Watchman ® LAA Closure Device (Boston Scientific, Natick, MA, USA) is a nitinol mesh basket with hooks to stabilise the device into the LAA walls. The diameter is equal to the length, so it is not suitable for shallow LAAs. A venous access sheath is inserted, the inter-atrial septum is punctured under fluoroscopy and TOE guidance, and the Watchman is deployed into the LAA. LAA closure devices provide stroke prevention in nonvalvular AF comparable to warfarin, with low complication rates. 9 Complications include cardiac tamponade, ischaemic stroke (from air emboli), pericarditis, transient myocardial ischaemia (from air emboli), arrhythmias, and device embolisation (requires surgical removal).
Rhythm control
For acute AF (<48 h), synchronised direct current cardioversion is the most effective way to restore sinus rhythm. 10 In haemodynamically unstable acute AF, it is the treatment of choice. This requires deep sedation or general anaesthesia. If AF has persisted for longer than 48 h, OACs must be taken for at least 3 weeks before electrical cardioversion and continued for 4 weeks after. If the patient is not anticoagulated, a TOE can exclude a LAA thrombus before cardioversion. Pharmacological cardioversion with antiarrhythmic agents (Table 3) can restore normal sinus rhythm in about 50% of patients with acute AF.
Catheter ablation
AF ablation has been shown to be more effective in maintaining sinus rhythm then anti-arrhythmic medications, with similar complication rates. 11 Mapping technologies are evolving, and ablation energies and techniques are changing. The indications for AF ablation are as a second-line therapy for those who are intolerant of antiarrhythmic drugs or refractory, symptomatic paroxysmal, persistent, or longstanding persistent AF. The target for ablation is complete isolation of the four PVs. There are two common ablation techniques: radiofrequency energy ('burning') or cryothermy ('freezing') (see below). For paroxysmal AF, pulmonary vein isolation (PVI) alone is usually sufficient. However, with persistent AF, an additional left atrial 'substrate' based ablation may be performed.
A TOE is required before an ablation procedure to exclude a LAA thrombus. The femoral venous access sheath is inserted, and ablation catheters are passed through the sheath and up into the right atrium. The intra-atrial septum is punctured (transseptal puncture) with fluoroscopy and TOE guidance, and the catheters are passed into the left atrium. A TOE view of the intra-atrial septum is acquired at between 45 and 90 , and 'tenting' of the thin, central, portion should be observed before puncture (Fig. 3 ). Too posterior a position will result in catheter perforation of the posterior atrial wall, and too anterior a position could result in perforation of the aorta.
Mapping systems
Several mapping systems are available to identify arrhythmia pathways and trigger sites. The CARTO system uses an electromagnetic field created by a magnet underneath the catheter table and the CARTOMERGE™ system incorporates this with a cardiac CT or MRI scan. The EnSite Precision™ mapping system uses three pairs of orthogonal skin patches on the patient's back, chest, and left leg to create an electrical field. The intracardiac catheter collects electrical data and constructs a 3D model of the cardiac chamber. The Rhythmia™ mapping system is a fast, high-density 3D mapping technology. The mapping catheter is a basket device and signals are acquired from 64 electrodes during each heartbeat.
Magnetic navigation
The stereotaxis system is a magnetically controlled navigation system that allows the operator to position mapping and ablation catheters inside the heart using a joystick. This system is useful in patients with congenital heart disease with anatomical constraints making access to intracardiac chambers more difficult by manual manipulation.
Ablation energies
Different energies can be used to interrupt aberrant conduction pathways.
Radiofrequency ablation uses radiofrequency current to heat tissue causing cellular necrosis with convective heat loss away from the site. Saline irrigation around the catheter tip allows a high energy concentration at the tip. A point-to-point catheter application is used in a continuous circle around each pulmonary vein ostium. Cryoablation uses cryogenic energy (between e50 C and e70 C) to cause tissue freezing and thus cellular necrosis. 12 Cryoablation is transiently reversible and therefore is used if heart block is a concern, for example when the aberrant pathways are close to the atrioventricular (AV) node. A cryoballoon consists of a floppy guide wire with a liquid nitrogen-filled balloon. The guidewire is inserted into a PV, under fluoroscopic guidance, and the balloon is inflated. The balloon is advanced slightly further, and occlusion is tested with a distal injection of radio-opaque contrast. The balloon is filled with liquid nitrogen (e50 C) and the tissue is cooled for 180e300 s. There are various balloon sizes (23 mm and 28 mm) available. For right-sided PV ablation, phrenic nerve conduction is monitored to minimise the risk of phrenic nerve damage (1e2%). The phrenic nerve is paced, and diaphragmatic contraction is monitored. The patient must not be paralysed at this stage of the procedure.
The endoscopic laser balloon ablation system (EAS) consists of a miniature 2F endoscope, a laser energy source, and a balloon. The central balloon shaft contains the endoscope and the laser. The endoscope guides the balloon into the PV. Higher energy is used along the anterior left atrial wall (thicker cardiac tissue), whereas the lower energy is used along the thinner posterior wall because it is very close to extracardiac structures, particularly the oesophagus. The radiofrequency hot balloon (RHB) is a compliant balloon with two lumens, one holding a guide wire and one an injection port for contrast and saline. The balloon is positioned under fluoroscopic guidance into a PV and a distal injection of contrast media again confirms complete occlusion. A radiofrequency generator heats up the luminal fluid to 70e75 C to heat the surrounding PV tissue.
The benefit of radiofrequency ablation is reduced exposure to fluoroscopy; however, catheter guidance is dependent on a mapping system. The balloon devices depend on fluoroscopy to position the balloon but do not require a 3D mapping system.
The complications of all ablation devices are vascular injury, pseudoaneurysms, haematomas, arteriovenous fistulae, oesophageal damage, pericardial effusions, and tamponade (1e2%). Strokes or TIAs are now rare, as patients continue anticoagulation over the peri-operative period. All ablation techniques have the potential to cause phrenic nerve injuries. These are usually transient, and most recover within 8 weeks. PV stenosis is more common with smaller balloons as they pass more distally into the PV. 13 Heparin is given during left-sided ablation procedures and is titrated to an activated clotting time of 250e300 s. Heparin may be antagonised by protamine. Warfarin or novel OACs are continued over the perioperative period.
Developments in pacing technology
Leadless pacing
The limitations of permanent pacemakers (PPM) are the generator battery lifespan, indwelling venous leads, and pacing leads crossing the tricuspid valve. This has led to the development of leadless pacing for patients who only require single chamber pacing (pacing mode VVI e ventricle sensed, ventricle paced, pacing inhibited).
14 This advancement will reduce the need for lead extraction procedures, which pull and distort cardiac chambers, risking myocardial damage and tamponade. It also reduces the risk of infective endocarditis and tricuspid regurgitation. There are two leadless pacing systems currently available: the leadless cardiac pacemaker (LCP) and the transcatheter pacing system (TPS). Both systems are inserted via a femoral sheath and guided into the right ventricle (RV) by a catheter. Both are small metallic complex devices that fix into the myocardium of the RV septum. The thin RV free wall is avoided to prevent perforation. Both are MRI compatible, and the battery life is greater than 10 yr.
The most suitable patients for leadless pacing devices are those with damaged upper central venous systems from previous devices (e.g. adults with congenital heart disease), indwelling catheter infections, chest wall radiotherapy, and trauma. They may be appropriate in renal failure patients to spare their veins for dialysis catheters, and to reduce the risk of lead infections from transient bacteraemia.
The complications include femoral venous injuries, cardiac perforation, device dislodgement, and wrong implantation site. Both systems have a proximal groove to allow them to be extracted via a snare, if incorrectly positioned.
These devices are currently limited to single chamber pacing, but developments to pair these devices with subcutaneous defibrillators are ongoing. The pacemaker occupies a volume of about 1 ml; thus, RV function should not be compromised. At the end of their lifespan, they are left in situ and a new device is deployed. Long term, risk of infection, device migration, and RV failure are unknown.
Subcutaneous ICDs
ICDs are used for primary prevention in patients with cardiomyopathies or channelopathies, and as secondary prevention for those who have survived a life-threatening arrhythmia. A subcutaneous ICD (S-ICD) provides a defibrillator system without leads in or on the heart. Complications from ICDs include lead fractures, lead failure, thrombus formation, vascular obstruction, tricuspid regurgitation, and cardiac perforation. Transvenous leads are a source for infection.
The indications for S-ICD are: primary or secondary prevention of life-threatening arrhythmias in patients with difficult central venous access (adults with congenital heart disease) or where the central venous access needs to be reserved for other catheter devices.
The S-ICD system consists of a 3 mm parasternal electrode (1e2 cm left of sternal midline) and is connected to a pulse generator inserted in a pocket (between serratus anterior and latissimus dorsi muscles) between the anterior and midaxillary line at the level of the left ventricular apex. The electrode has an 8 cm shocking coil (flanked by two sensing electrodes) and is tunnelled subcutaneously from this pocket to a position 1 cm above the xiphoid process. A second incision is made at the xiphoid process; the shocking electrode is tunnelled to the left of the sternum towards the substernal notch using a peel-away sheath. 15 The distal sensing electrode is positioned at the manubrium sternum and the proximal sensing electrode at the xiphoid process.
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BJA Education -Volume 18, Number 11, 2018 S-ICD is completely extravascular, extracardiac, and extrathoracic; therefore, the risk of pneumothorax, cardiac perforation, and endocarditis are significantly reduced, and subsequent lead extraction procedures are avoided. However, they lack pacing capability, the pulse generator is large, and the battery life is short. To compensate for the lack of pacing capability, a S-ICD may be combined with a leadless pacemaker in the future.
Complications of S-ICD include under-or over-sensing of the ECG with subsequent missed or inappropriate shocks. Other complications include pocket infection, device erosion, patient discomfort, and wound haematoma.
Cardiac resynchronisation therapy
Ischaemic heart disease and heart failure may cause dyssynchronous left ventricular wall motion with left bundle branch block seen on a surface ECG. Pacemakers cause rightto-left septal depolarisation; therefore, right ventricular filling occurs first and encroaches on left ventricular filling, decreasing stroke volume and cardiac output. By pacing both the right and left ventricles simultaneously, cardiac resynchronisation therapy (CRT) replicates left-to-right septal depolarisation, mimicking normal physiology. With CRT devices, three transvenous leads are inserted into the heart under fluoroscopic guidance (beware of three leads on a chest X-ray!). One lead is in the right atrium, one in the right ventricle, and the third in a branch of the coronary sinus to pace the left ventricle. The generator box is implanted subcutaneously or sub-pectorally.
The indication for CRT is New York Heart Association class II or III heart failure with a reduced left ventricular ejection fraction or less than 35%, a QRS complex of greater than 130 ms, and left bundle branch block. 16 CRT has been shown to reduce morbidity and mortality; however, up to 30% fail to respond (non-responders). A defibrillator may be combined with a CRT device (CRT-D).
The most common complications are coronary sinus dissection, bleeding, and pneumothorax.
Anaesthesia in the EP laboratory
Patients
A diverse group of patients present for EP procedures, from young patients with cardiomyopathies or channelopathies to elderly patients with numerous comorbidities. Some procedures can be performed under local anaesthesia with or without sedation in accordance with the local and national sedation guidelines.
17e19 Children, young adults, and anxious patients require sedation administered by an anaesthetist or general anaesthesia. If the procedure is anticipated to be protracted, and involves a TOE, transseptal puncture, or device deployment, a general anaesthetic is preferred. The personal preferences of both the patient and cardiologist should be considered.
Adult congenital heart disease
In adults with corrected congenital heart disease, sequelae, such as tachyarrhythmias, are a cause of sudden decompensation and deterioration in cardiac function. The patients may have complex anatomy, prosthetic valves, baffles, and patches, making the passage of intracardiac catheters more difficult and hazardous. Adults with congenital heart disease may have spent protracted periods of time in hospital as children, and therefore present unique psychological demands.
Preoperative assessment
All patients should be assessed before the operation, comorbidities identified, and baseline functional status quantified. Right-sided ablation procedures are suitable for day surgery, but left-sided ablations involving a transseptal puncture stay overnight in case of pericardial effusion and/or cardiac tamponade. Cardiac catheter laboratories may be situated in remote areas of the hospital away from the operating department. Anaesthesia is usually induced in the laboratory, where it can be noisy with many distractions. The staff are less familiar with general anaesthesia and care of the anaesthetised patient. Extensive application of ECG electrodes and patches for mapping, ablation, and defibrillation is best done with the patients awake and able to move themselves. It is also important to ascertain if the catheter laboratory table tips and ensure that a radiographer who can operate the table is present during induction. Access to the patient may be limited, because of the C arm and lateral fluoroscopy screens. Potentially difficult intubations should be anticipated and appropriate airway equipment available. Lights may be dimmed to improve screen visualisation for the cardiologists.
The standard monitoring as for any general anaesthetic is mandatory. Large-bore peripheral venous access is usually adequate; however, an arterial line may be placed for highrisk left-sided procedures including ventricular tachycardia (VT) ablation, patients with severe ventricular dysfunction, or blood gas monitoring.
Exposure to radiation for laboratory staff is also a consideration, and measures to minimise fluoroscopy time are important. In addition to standard lead aprons and thyroid shields, there are now lead hats and lead-lens glasses to confer further protection to personnel and comply with the Ionising Radiation Medical Exposure Regulations 2000 (IRMER).
Anaesthesia is induced with opioids (fentanyl), induction agents (propofol, etomidate), and neuromuscular blockers (atracurium, rocuronium). Anaesthesia is maintained with volatile agents (sevoflurane, isoflurane, desflurane) or total intravenous anaesthesia (TIVA). Vasoconstrictors such as metaraminol are used to maintain arterial pressure.
Familiarity with TOE views to aid with safe transseptal puncture can be helpful, particularly as more procedures are performed on uninterrupted OAC therapy or heparin is administered upon venous access rather than after left atrial access.
For accurate mapping of arrhythmia pathways, immobility and prevention of coughing is paramount; however, there are mechanisms to compensate for respiratory excursion within the mapping software.
Conscious sedation can be provided with a benzodiazepine/opioid technique or with target, controlled infusions of propofol and/or remifentanil.
All pressure points should be appropriately padded and protected. The catheter laboratory tables are narrow, and therefore secure positioning of larger patients can be challenging. A nasopharyngeal or oropharyngeal temperature probe should be placed, and the patient's temperature maintained with a forced-air warming blanket. Urinary catheters should be considered for longer procedures.
Smooth reversal of neuromuscular block and avoidance of coughing during extubation is important to avoid groin haematoma after catheter removal. The patient should then be transferred to a recovery area with trained recovery staff and appropriate monitoring.
Postoperative pain is managed with local anaesthetic infiltration at catheter puncture sites and simple analgesics such as paracetamol, codeine, or non-steroidal anti-inflammatory drugs.
Specific procedures and anaesthetic considerations
Flutter ablation
Atrial flutter usually arises from the right atrium and is ablated by burning a single line between the inferior vena cava and the tricuspid isthmus (CTI ablation). It usually does not involve transseptal puncture, or TOE. The risk of tamponade is low, and it can be performed as a day case, under sedation or a GA with a supraglottic airway device.
AF ablation using the Cryoballoon (Arctic Front Advance™)
Left-sided ablation procedures require transseptal puncture guided by TOE. During Cryoablation of the right upper PV the phrenic nerve is paced, and diaphragmatic contraction monitored, to exclude phrenic nerve damage. This precludes the use of neuromuscular block after initial induction of anaesthesia and intubation.
Ablation using radiofrequency energy
The radiofrequency catheter tip is irrigated with saline, resulting in the patient receiving an additional 1.5 L of saline during an average AF ablation. It is therefore important to limit i.v. fluid administration and consider catheterisation at the end of the procedure to avoid patient discomfort and fidgeting causing groin haematomas.
TOE probes have previously been left in the oesophagus during the AF ablation, but pulled back out of the field of the operator's vision on the fluoroscopy screen, to avoid opposing the oesophagus against the left atrium and increasing the chance of thermal damage. The probe was then reinserted at the end of the procedure to check for pericardial effusions. There is now more reluctance to do this, because of concerns about oesophageal damage after heparinisation. The cardiologists may perform a transthoracic echo at the end of the case and give proton pump inhibitors for 4 weeks after ablation.
Atrioventricular nodal re-entry tachycardia/atrial tachycardia ablation
In procedures where it is essential to stimulate an arrhythmia to define the area of its origin, it is preferable to avoid volatile anaesthetic agents. This includes atrial tachycardias, and AV nodal and AV re-entry tachycardias such as Wolfe ParkinsoneWhite and VT ablation. The arrhythmia may be provoked with the patient awake, and then anaesthesia can subsequently be induced and maintained with a targetcontrolled total intravenous technique, using propofol and/ or remifentanil. However, there is limited evidence that volatile anaesthetic agents do suppress arrhythmias or affect the outcomes of ablation procedures. 20 
VT ablation
For VT, the approach may require epicardial ablation in addition to endocardial ablation. Pericardial access is gained by sub-xiphisternal puncture, with risks that include damage to liver, stomach, and internal thoracic artery. Ablation epicardially is directed away from major coronary vessels, but tamponade may occur because of irrigated fluid accumulation or epicardial bleeding. In addition, damage to the left phrenic nerve has been reported, and pacing epicardially along the left lateral ventricular wall may be required during the procedure to map the course of the nerve.
ICD insertion
The consensus is that general anaesthesia should be avoided in these patients. However, this depends on the patient, the indication for the ICD, and cardiac function. Young people who are having an ICD for primary prevention are safely and easily managed with general anaesthesia, especially if the device is to be tested. S-ICDs are particularly painful to insert and probably require a simple general anaesthetic with a supraglottic airway. Defibrillation testing is performed less often, as it is rare for it to be unsuccessful and may lead to haemodynamic compromise. However, it may be required on an individual patient basis if there are concerns about suboptimal lead sensing and impedance parameters.
TOE and cardioversion
This is a short procedure but requires deep anaesthesia for TOE with rapid emergence. A favoured technique is profound anaesthesia with a short-acting opiate and propofol, careful insertion of the TOE probe, followed by airway management with a supraglottic airway. This avoids neuromuscular block and the patient rapidly resumes spontaneous ventilation. The TOE probe should be inserted before the laryngeal mask airway to prevent pharyngeal or oesophageal damage.
Conclusions
EP is a rapidly evolving specialty demanding increasing support from cardiac anaesthetists. The principles of anaesthesia in remote areas are applicable. It is important to understand these newer technologies and anticipate the potential complications in order to respond appropriately.
Patients will increasingly present for non-cardiac surgery having undergone ablation procedures or with devices in situ. Three pacing leads on a chest X-ray should alert the anaesthetist to CRT and the implications of this for cardiac function.
An understanding of the advances in EP is essential for all anaesthetists to develop and deliver a high-quality cardiac anaesthetic service and provide the best care for EP patients presenting for non-cardiac surgery.
